AC
ACTU.US Actuate Therapeutics, Inc. Common stock
- Market cap
- USD 16.3M
- P/E
- -
- P/B
- 7.34x
- ROE
- -2,121.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ACTU.US undervalued?
Graham numberThe Graham number of Actuate Therapeutics, Inc. Common stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Actuate Therapeutics, Inc. Common stock fundamental analysis
No fundamental analysis for Actuate Therapeutics, Inc. Common stock yet.
Actuate Therapeutics, Inc. Common stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neurobla…
Full company profileActuate Therapeutics, Inc. Common stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Actuate Therapeutics, Inc. Common stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -20.2M | -25.0M | -25.2M | -22.5M | -21.2M |
| EBITDA | 63.6K | 273K | -2.14M | -22.2M | -21.1M |
| Net Income | -20.2M | -24.7M | -27.3M | -22.2M | -21.0M |
| EPS | -1.34 | -1.65 | -1.40 | -1.06 | -0.88 |
| Balance Sheet | |||||
| Total Assets | 20.5M | 3.00M | 9.32M | 14.0M | 5.20M |
| Total Liabilities | 5.65M | 103M | 9.21M | 6.11M | 4.21M |
| Shareholders' Equity | 14.8M | -99.6M | 104K | 7.92M | 989K |
| Cash & Short-term Investments | 20.4M | 2.96M | 8.64M | 13.2M | 4.43M |
| Total Debt | 405K | - | 405K | 405K | 405K |
| Cash Flow | |||||
| Operating Cash Flow | -17.8M | -21.6M | -21.8M | -19.2M | -18.8M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 12.00 |
| Free Cash Flow | -17.8M | -21.6M | -21.8M | -19.2M | -18.8M |
| Ratios | |||||
| ROE | -135.9% | - | -26,189.1% | -280.5% | -2,121.5% |
| ROA | -98.4% | -826.0% | -292.8% | -158.4% | -403.6% |
| Debt to Equity | 0.03x | - | 3.89x | 0.05x | 0.41x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Actuate Therapeutics, Inc. Common stock dividends
Actuate Therapeutics, Inc. Common stock has not paid dividends in the last 4 fiscal years.
Who owns Actuate Therapeutics, Inc. Common stock
- Insiders 14.67%
- Institutions 24.50%
- Public & others 60.84%
- Shares outstanding 55.0M
- Free float 19.0M
Top funds holding ACTU.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 287K | 0.52% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 63.6K | 0.12% | -0.21% | Sep 2026 |
| iShares Micro-Cap ETF | 34.7K | 0.06% | 0.00% | Oct 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 22.9K | 0.04% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 13.6K | 0.02% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 12.3K | 0.02% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 5.10K | 0.01% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 3.49K | 0.01% | -82.81% | Aug 2026 |
| 1290 VT Micro Cap K | 1.70K | 0.00% | 0.00% | Sep 2026 |
| BlackRock Small Cap Index V.I. I | 91.00 | 0.00% | -93.59% | Jun 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 54.00 | 0.00% | +42.11% | Jun 2026 |
| AXAWF Global Dynamic Allocation I CapUSD | 2.00 | 0.00% | 0.00% | Feb 2026 |
Top institutions holding ACTU.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BIOS CAPITAL MANAGEMENT, LP | 10.0M | 41.85% | 0.00% | Jun 2026 |
| Voss Capital LLC | 1.73M | 7.18% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 393K | 1.64% | -1.77% | Jun 2026 |
| Palogic Value Management LP | 200K | 0.83% | +100.00% | Jun 2026 |
| AQR Capital Management LLC | 127K | 0.53% | +370.30% | Jun 2026 |
| Geode Capital Management, LLC | 113K | 0.47% | -50.71% | Jun 2026 |
| Texas Capital Bank Wealth Management Services Inc | 103K | 0.43% | +8.48% | Jun 2026 |
| Millennium Management LLC | 96.7K | 0.40% | 0.00% | Jun 2026 |
| BlackRock Inc | 90.0K | 0.37% | -78.92% | Jun 2026 |
| ABS Investment Management LLC | 73.2K | 0.30% | 0.00% | Jun 2026 |
| ABS Direct Equity Fund LLC | 73.2K | 0.30% | +46.37% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 54.5K | 0.23% | -12.93% | Jun 2026 |
| Rock Creek Group, LP | 39.3K | 0.16% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 39.1K | 0.16% | 0.00% | Jun 2026 |
| HighTower Advisors, LLC | 36.5K | 0.15% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 35.5K | 0.15% | +186.09% | Jun 2026 |
| Sfmg LLC | 33.0K | 0.14% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 28.2K | 0.12% | 0.00% | Jun 2026 |
| Bridgeway Capital Management, LLC | 23.5K | 0.10% | -24.21% | Jun 2026 |
| State Street Corp | 21.9K | 0.09% | -66.91% | Jun 2026 |
Actuate Therapeutics, Inc. Common stock company profile
- Company name
- Actuate Therapeutics, Inc. Common stock
- Ticker
- ACTU.US
- Exchange
- USA Stocks
- Listed since
- Aug 13, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Fiscal year end
- December
- Address
- 1751 River Run, Fort Worth, TX, United States, 76107
- Phone
- 817 887 8455
- Website
- actuatetherapeutics.com
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Actuate Therapeutics, Inc. Common stock management
4- Mr. Daniel M. SchmittCEO, President & Director · born 1962
- Dr. Andrew P. Mazar Ph.D.Co-Founder & COO · born 1962
- Mr. Paul J. Lytle CPAChief Financial Officer · born 1968
- Dr. Alan Kozikowski Ph.D.Scientific Founder and Advisor · born 1950